Metropolis Healthcare Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Metropolis Healthcare Ltd trades at ₹586, in a confirmed uptrend and 16 weeks into that stage. That is +11.4% against its own 200-day average. It sits at 98% of a 52-week range of ₹422 to ₹589. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 4 straight weeks.

Today the stock is in a confirmed uptrend — week 16 of stage 2, confirmed. At ₹586 it trades +11.4% versus its 200-day average and sits at 98% of its 52-week range (₹422–₹589).

Against the market, two honest reads. Cumulative: over the last 7.4 years the stock moved +141% while the NIFTY 500 moved +136% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 4 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

Story check

Metropolis Healthcare Ltd's story is not scored yet against the markers our research file set on 31 May 2026. Where it sits in its own cycle: Not stated in the research file. Still open: Three documented management consistency failures in four concalls — Core Diagnostics margin target, center-to-lab ratio timeline, and M&A moratorium — all on core thesis pillars.

Our read, 31 May 2026. Organic-led margin expansion cycle confirmed — but PE at 58.6x offers thin safety margin while management consistency track record is mixed.

What is proven. Organic-led margin expansion cycle confirmed — but PE at 58.6x offers thin safety margin while management consistency track record is mixed.

What is not proven yet. Three documented management consistency failures in four concalls — Core Diagnostics margin target, center-to-lab ratio timeline, and M&A moratorium — all on core thesis pillars.

Layer 1 read, 19 July 2026 — KEEP. Real margin-expansion story but the multiple has already re-rated — expanding, RICH 60x PE with EXTREME MoS and a reversal-heavy guidance record. Revenue grew to Rs 425 Cr with a 700bps YoY Q4 margin jump, a genuine organic-led operating-leverage cycle. But unlike the rest of the batch this multiple is EXPANDING not compressing, sits at an absolutely RICH 60x with an EXTREME -49% MoS and IMPOSSIBLE implied growth (⚠ model), and management repeatedly reversed itself — downgrading the Core Diagnostics margin target and flip-flopping on its M&A moratorium.

What would change Layer 1’s mind. The multiple beginning to COMPRESS (PE falling from 60x toward its 58.1 median) while organic EBITDA margin clears the 25.5% H1 FY27 milestone — that would flip this from a spent re-rating into a fresh de-rating-into-earnings setup and lift it toward P1; conversely, organic revenue growth printing below the 13% FY27 milestone would strain the thesis toward VIOLATED.

Layer 2 read, 19 July 2026 — BENCH. Real margin engine, but a -49%-overpriced compounder inside a Diagnostics capacity glut with FII exiting — trackable, not buyable now. The earnings inflection is genuine: Q4 OPM +700bps on 14% volume with lab productivity up 14% and no new labs, OCF operations-backed and FCF doubling. But you pay for it at MoS -49% and a monotonic-expanding ~58x, while the sector shows a capex SUPPLY_FLOOD (+68.4% YoY, CWIP +210.7%) with institutions absent and FII cutting this name from 16.7% to 10.4% over six quarters. Management has slipped on margin and M&A guidance three times in four concalls.

What would change Layer 2’s mind. A meaningful de-rating that pulls MoS back toward par (into the -20s or better) OR sector capex_read flipping from SUPPLY_FLOOD to NEUTRAL/WITHDRAWAL with FII re-entering — either would clear the specific external negative and flip BENCH→ADVANCE. Conversely, a clean concall with delivered guidance (ending the consistency slippage) alongside FII stabilization would also support promotion.

What the company does. FY26 organic revenue +13.7% (beat guidance of 12-13%), organic EBITDA margin 25.9% (+140bps), PAT Rs 191 Cr (+31% YoY), Q4 PAT Rs 51 Cr (+75% YoY) —. Core Diagnostics turned EBITDA-positive (high single-digit in Q4 from -2% at acquisition), eliminating the margin drag; group EBITDA margin target 27-28% set for FY27-29 —. Management credibility undermined by three documented target changes on Core Diagnostics margin, center-to-lab ratio, and M&A moratorium in the past four concalls —.

Lever 1 · Operating leverage — BUILDING. 212 labs absorbing 14-15% volume growth without proportional cost additions; lab productivity +14% FY26; FY27 no new labs guided. What proves it keeps working: Operating Leverage on Fixed Lab Base. It stops working if Two consecutive quarters of Core Diagnostics missing its stated improvement path, OR organic EBITDA margin declining versus FY26 exit rate.

Lever 2 · Value-added mix — BUILDING. Specialty at 37% organic FY26 (+16% YoY), targeting 40% FY27; True Health 19% organic (+21% YoY), targeting 25%+ in 2-3 years — both improve RPP and gross margins. What proves it keeps working: Specialty and True Health Mix Shift. It stops working if Two consecutive quarters of Core Diagnostics missing its stated improvement path, OR organic EBITDA margin declining versus FY26 exit rate.

Lever 3 · Management change — BUILDING. Core Diagnostics EBITDA moved from -2% at acquisition to high single-digit Q4 FY26; 20%+ target by FY28-end removes acquired revenue from margin drag. What proves it keeps working: Core Diagnostics Integration — Margin Drag to Contributor. It stops working if Two consecutive quarters of Core Diagnostics missing its stated improvement path, OR organic EBITDA margin declining versus FY26 exit rate.

Lever 8 · Demerger or value unlock — BUILDING. Digital at 25% of FY26 revenue; physical brand reduces customer acquisition cost versus health-tech competitors; CLM engine improving retention. What proves it keeps working: Digital Channel Scale — Lower CAC, Higher LTV. It stops working if Two consecutive quarters of Core Diagnostics missing its stated improvement path, OR organic EBITDA margin declining versus FY26 exit rate.

Sources: our stock research file (31 May 2026) · quarterly results through Jun 26 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Metropolis Healthcare Ltd reported ₹450 Cr of revenue in the Jun 26 quarter, +16.6% year on year. That is the 12th straight quarter of year-on-year growth. Over 10 years it has compounded at 13.2% a year. The last full year, FY26, came in at ₹1,646 Cr. The last four reported quarters add to ₹1,710 Cr.

FY26 revenue came in at ₹1,646 Cr (+23.7% on the year), capping 10 years at 13.2% compound. The latest quarter (Jun 26) printed ₹450 Cr, +16.6% year on year — the 12th consecutive quarter of year-over-year growth.

Pace check: the last four quarters averaged +22.0% growth against the decade's 13.2% — the current year is running faster than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +21.8% over the last 4 quarters against +17.3%/yr over the last 8 — accelerating; TTM profit +33.6% vs +21.3%/yr — accelerating.

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Metropolis Healthcare Ltd's operating margin is 25.0% in the Jun 26 quarter, +2.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 23.0% to 29.0%. The current quarter sits inside that band.

Why this happened. Metropolis shifted from expansion-led capex to utilization-led productivity. FY26 saw 14-15% volume growth absorbed by the existing 212-lab network with capex of Rs 65 Cr. Lab productivity improved 14% on the same fixed base. Q4 organic margin 27.2% was driven by this operating leverage. FY27 guidance of 125-150 bps margin improvement assumes continued fixed-cost leverage as volumes grow 8-9% on top of the FY26 base.

The latest quarter's operating margin is 25.0%, +2.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 23.0%–29.0%.

Why the margin moved: operating margin went +1.4 pp year on year while gross margin went +1.1 pp — the gain came mostly from the gross line: input costs and pricing.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Metropolis Healthcare Ltd earned ₹57.0 Cr of net profit in the Jun 26 quarter, +26.7% year on year. It is the 5th consecutive quarter of growth. Full-year FY26 profit was ₹191 Cr. The 10-year compound rate is 8.8%. That is 12.7% of the quarter's revenue. The same quarter a year earlier earned ₹45.0 Cr.

Jun 26 profit was ₹57.0 Cr, +26.7% year on year — the 5th consecutive quarter of growth. On the full year, FY26 printed ₹191 Cr (+30.8%), and the 10-year compound rate is 8.8%.

Why profit moved: revenue contributed +16.6% and the margin +2.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.

Pace comparison, last four quarters: profit +37.7% vs revenue +22.0%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 189% of Metropolis Healthcare Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹351 Cr of operating cash against ₹191 Cr of profit. After ₹288 Cr of capital spending, ₹63.0 Cr was left as free cash.

FY26: operating cash of ₹351 Cr against reported profit of ₹191 Cr, leaving free cash of ₹63.0 Cr after ₹288 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 189% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

Why conversion sits at 189%: the cash cycle held roughly steady between FY21 and FY26 — so conversion tracks profitability rather than the cycle.

Router verdict: the bigger cash user is investment — capital spending ran 2.4× depreciation over three years, so the next section's job is to check what that build-out is buying.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Metropolis Healthcare Ltd's cash conversion cycle runs −57 days in FY26, down from −56 days in FY21. Capital spending ran ₹797 Cr over the last 3 years. At FY26 sales of ₹1,646 Cr each day of that cycle holds about ₹4.5 Cr, so roughly ₹−257 Cr sits inside the business at any moment.

FY26: debtors at 38 days, inventory at 51 days — roughly 1.7 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of −57 days, tighter than FY21's −56.

The full loop: cash goes out to suppliers and production on day 0; stock waits 51 days to sell; customers pay about 38 days after that; and suppliers themselves are paid at 146 days — netting out to the −57-day cycle.

In money terms: at FY26 sales of ₹1,646 Cr, each day of the cycle holds about ₹4.5 Cr — so the −57-day loop keeps roughly ₹−257 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹797 Cr over the last 3 fiscal years against ₹337 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹0.0 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

Metropolis Healthcare Ltd earns a ROCE of 18% in FY26. That is up from a trough of 15% in FY25. Return on invested capital clears the cost of that capital by +1.6 percentage points, so growth here adds value rather than only size. The wiring behind it is 11.6% net margin on 0.77× asset turns.

FY26 ROCE is 18%, recovered from a FY25 trough of 15% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (FY26): 11.6% net margin × 0.77× asset turns × 1.41× balance-sheet leverage ≈ 12.6% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.

The capstone test — ROIC − WACC: 13.6% − 12.0% = a +1.6 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

Metropolis Healthcare Ltd carries total debt of ₹232 Cr against shareholder equity of ₹1,525 Cr as of Mar 26, a debt-to-equity of 0.15 — effectively unlevered. On the annual view that ratio went from 0.43 in FY22 to 0.15 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.

Mar 26: total debt of ₹232 Cr against shareholder equity of ₹1,525 Cr — a debt-to-equity of 0.15. On the annual view, debt-to-equity went from 0.43 (FY22) to 0.15 (FY26). The returns on this page are earned, not borrowed.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

Domestic institutions added 7.7 points of Metropolis Healthcare Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 35.1% of the company. Foreign institutions moved −7.2 points over the same window, to 11.0%. The register is read on the four disclosed classes only; nothing is inferred between filings.

Why this happened. Core Diagnostics was acquired at -2% EBITDA margins and has completed its 4-quarter turnaround commitment, exiting Q4 FY26 at high single-digit margins. The path to 20%+ by end of FY28 via platform integration and procurement synergies is articulated. However, the original guidance was for Core Diagnostics to achieve Metropolis-level margins (~23-24%) within 3 years; this was downgraded to 20%+ in May 2026 without explanation, reducing the magnitude of this driver. Regional acquisitions are performing above group average margins.

The register over the last two years — Domestic institutions: +7.7 points over 8 quarters to 35.1%; Foreign institutions: −7.2 points over 8 quarters to 11.0%; Promoters: −0.8 points over 8 quarters to 48.9%.

Why the register moved: rotation — foreign institutions −7.2 points against domestic institutions +7.7 points over 8 quarters, with promoters −0.8 points — one class of institutions handing the register to the other, not a verdict change by the people closest to the numbers.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Metropolis Healthcare Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Metropolis Healthcare Ltd trades at 58.4× P/E, mid-range by its own standards (51st percentile). Its long-run median P/E is 58.2×, measured across 7.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Why this happened. Digital revenue reached 25% of total FY26 revenue via three channels: Metropolis app, website, and a CLM engine for retention. Management differentiates Metropolis digital from pure-play health-tech competitors via the physical brand's lower customer acquisition cost and higher customer lifetime value. The unit economics argument is plausible given the 50+ year brand and 750-town presence, though management has not quantified the CAC differential in any concall.

Today's P/E of 58.4× is mid-range by its own standards (51st percentile), against a long-run median of 58.2× measured over 7.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

Why the multiple sits where it does: over the past year annual EPS moved +31.0% against a +13.5% price move — earnings outran the price, pushing the multiple DOWN its own range.

The price move, decomposed: over 5y, of the −4.9%/yr price move, ~−3.4%/yr came from earnings growth and ~−1.5 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.

Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Metropolis Healthcare Ltd reads as mixed on its fundamental arc. Mixed — no clean majority across the growth curves, ROCE holding at 16.8% — the per-curve reads carry the story. The read is built from 12 quarters across 4 curves, on full evidence.

Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.

4-Factor Sector Score

62.3/100 — rank 3 of 9 in Diagnostics · 100% evidence confidence

Metropolis Healthcare Ltd scores 62.3 out of 100 against the 9 companies it is compared with in Diagnostics, ranking 3. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 26.3 + 11.6 + 14.4 + 10 = 62.3. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Said versus delivered

What Metropolis Healthcare Ltd's management promised, set against what actually arrived — 4 tracked promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met.

Pricing History Rewritten · 5 August 2026. In May 2026, management said Metropolis had taken a price increase every year over the prior 2-3 years and that only the current year had been deferred. The August 2026 call instead said the last increase occurred in January 2023, which implies no increases during the intervening period and materially changes the basis for analyzing realization growth.

Center-to-Lab Ratio Reporting Reversed · 5 August 2026. May 2026 reported that the center-to-lab ratio had improved to 24:1, whereas the August 2026 call reported a current ratio of 1:21 while also claiming it had improved from 1:21 a year earlier. Even allowing for notation differences, the reported current figure has moved from 24 centers per lab to 21 centers per lab without an explanation of a changed definition, acquisition impact, or lab consolidation methodology.

Specialty Mix Target Raised Without Reconciliation · 5 August 2026. In May 2026, management expected specialty to reach approximately 40% of revenue for the year. By August 2026, management was already reporting a 40% contribution and had raised the stated target to 45%, a material five-point increase with no explanation of what changed or how the higher target affects the growth and realization outlook.

🚨 Core Diagnostics Long-Term Margin Target Downgraded · 14 May 2026. In the Nov 2025 call, management explicitly stated that Core Diagnostics would be brought to Metropolis levels of margin within 3 years of the acquisition, and directly confirmed the specific ~23-24% figure when asked by an analyst. In the May 2026 call, this same 3-year commitment is repositioned as 20% plus EBITDA for Core - a materially lower threshold that now sits well below Metropolis's own FY26 organic margin of 25.9%, with no explanation offered for the reduced ambition.

Every quote above is taken word for word from the company’s own earnings calls.

Frequently asked questions